Cargando…
COVID-19 symptom-onset to diagnosis and diagnosis to treatment intervals are significant predictors of disease progression and hospitalization in high-risk patients: A real world analysis
BACKGROUND: Coronavirus disease (COVID-19) is overwhelming healthcare systems worldwide. This study aimed to elucidate factors that influence disease progression to pneumonia and hospitalization before and after antiviral treatment for COVID-19 in an outpatient setting. METHODS: A total of 206 high-...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889256/ https://www.ncbi.nlm.nih.gov/pubmed/36774815 http://dx.doi.org/10.1016/j.resinv.2023.01.002 |
_version_ | 1784880692461568000 |
---|---|
author | Shimizu, Hideyasu Kawase, Jin Hayashi, Masamichi Imaizumi, Kazuyoshi Ito, Yuji Okazawa, Mitsushi |
author_facet | Shimizu, Hideyasu Kawase, Jin Hayashi, Masamichi Imaizumi, Kazuyoshi Ito, Yuji Okazawa, Mitsushi |
author_sort | Shimizu, Hideyasu |
collection | PubMed |
description | BACKGROUND: Coronavirus disease (COVID-19) is overwhelming healthcare systems worldwide. This study aimed to elucidate factors that influence disease progression to pneumonia and hospitalization before and after antiviral treatment for COVID-19 in an outpatient setting. METHODS: A total of 206 high-risk patients with COVID-19 were treated with sotrovimab, remdesivir, and molnupiravir at the Toshiwakai clinic between January 4 and April 30, 2022. Of these, 49 patients visited the Toshiwakai clinic directly and were treated immediately after diagnosis (Toshiwakai-clinic study group). The remaining patients were diagnosed elsewhere, and of these, 102 patients were quarantined at home (health-center study group) and 55 at designated facilities (quarantine-facility study group) before being referred to Toshiwakai clinic. Patients were categorized into those with mild and moderate COVID-19, based on the presence of pneumonia at the initial visit to Toshiwakai clinic. RESULTS: The symptom-onset-to-diagnosis and diagnosis-to-treatment intervals were significant predictors of moderate disease. Age, dyspnea, and diagnosis-to-treatment interval at the first visit to Toshiwakai clinic were significant predictors for hospitalization even after antiviral treatment. Although the symptom-onset-to-diagnosis interval did not differ among the three study groups, the diagnosis-to-treatment and symptom-onset-to-treatment intervals were significantly longer in the health-center and quarantine-facility study groups than in the Toshiwakai-clinic study group. CONCLUSION: The symptom-onset-to-diagnosis and diagnosis-to-treatment intervals reflect diagnostic and interventional delays, respectively, which are closely related to the current COVID-19 clinical management protocol. Easy access to the clinics and immediate antiviral treatment after diagnosis may be the best methods to prevent disease progression and hospitalization in high-risk patients. |
format | Online Article Text |
id | pubmed-9889256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Published by Elsevier B.V. on behalf of The Japanese Respiratory Society. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98892562023-02-01 COVID-19 symptom-onset to diagnosis and diagnosis to treatment intervals are significant predictors of disease progression and hospitalization in high-risk patients: A real world analysis Shimizu, Hideyasu Kawase, Jin Hayashi, Masamichi Imaizumi, Kazuyoshi Ito, Yuji Okazawa, Mitsushi Respir Investig Original Article BACKGROUND: Coronavirus disease (COVID-19) is overwhelming healthcare systems worldwide. This study aimed to elucidate factors that influence disease progression to pneumonia and hospitalization before and after antiviral treatment for COVID-19 in an outpatient setting. METHODS: A total of 206 high-risk patients with COVID-19 were treated with sotrovimab, remdesivir, and molnupiravir at the Toshiwakai clinic between January 4 and April 30, 2022. Of these, 49 patients visited the Toshiwakai clinic directly and were treated immediately after diagnosis (Toshiwakai-clinic study group). The remaining patients were diagnosed elsewhere, and of these, 102 patients were quarantined at home (health-center study group) and 55 at designated facilities (quarantine-facility study group) before being referred to Toshiwakai clinic. Patients were categorized into those with mild and moderate COVID-19, based on the presence of pneumonia at the initial visit to Toshiwakai clinic. RESULTS: The symptom-onset-to-diagnosis and diagnosis-to-treatment intervals were significant predictors of moderate disease. Age, dyspnea, and diagnosis-to-treatment interval at the first visit to Toshiwakai clinic were significant predictors for hospitalization even after antiviral treatment. Although the symptom-onset-to-diagnosis interval did not differ among the three study groups, the diagnosis-to-treatment and symptom-onset-to-treatment intervals were significantly longer in the health-center and quarantine-facility study groups than in the Toshiwakai-clinic study group. CONCLUSION: The symptom-onset-to-diagnosis and diagnosis-to-treatment intervals reflect diagnostic and interventional delays, respectively, which are closely related to the current COVID-19 clinical management protocol. Easy access to the clinics and immediate antiviral treatment after diagnosis may be the best methods to prevent disease progression and hospitalization in high-risk patients. Published by Elsevier B.V. on behalf of The Japanese Respiratory Society. 2023-03 2023-02-01 /pmc/articles/PMC9889256/ /pubmed/36774815 http://dx.doi.org/10.1016/j.resinv.2023.01.002 Text en © 2023 [The Author/The Authors] Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Shimizu, Hideyasu Kawase, Jin Hayashi, Masamichi Imaizumi, Kazuyoshi Ito, Yuji Okazawa, Mitsushi COVID-19 symptom-onset to diagnosis and diagnosis to treatment intervals are significant predictors of disease progression and hospitalization in high-risk patients: A real world analysis |
title | COVID-19 symptom-onset to diagnosis and diagnosis to treatment intervals are significant predictors of disease progression and hospitalization in high-risk patients: A real world analysis |
title_full | COVID-19 symptom-onset to diagnosis and diagnosis to treatment intervals are significant predictors of disease progression and hospitalization in high-risk patients: A real world analysis |
title_fullStr | COVID-19 symptom-onset to diagnosis and diagnosis to treatment intervals are significant predictors of disease progression and hospitalization in high-risk patients: A real world analysis |
title_full_unstemmed | COVID-19 symptom-onset to diagnosis and diagnosis to treatment intervals are significant predictors of disease progression and hospitalization in high-risk patients: A real world analysis |
title_short | COVID-19 symptom-onset to diagnosis and diagnosis to treatment intervals are significant predictors of disease progression and hospitalization in high-risk patients: A real world analysis |
title_sort | covid-19 symptom-onset to diagnosis and diagnosis to treatment intervals are significant predictors of disease progression and hospitalization in high-risk patients: a real world analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889256/ https://www.ncbi.nlm.nih.gov/pubmed/36774815 http://dx.doi.org/10.1016/j.resinv.2023.01.002 |
work_keys_str_mv | AT shimizuhideyasu covid19symptomonsettodiagnosisanddiagnosistotreatmentintervalsaresignificantpredictorsofdiseaseprogressionandhospitalizationinhighriskpatientsarealworldanalysis AT kawasejin covid19symptomonsettodiagnosisanddiagnosistotreatmentintervalsaresignificantpredictorsofdiseaseprogressionandhospitalizationinhighriskpatientsarealworldanalysis AT hayashimasamichi covid19symptomonsettodiagnosisanddiagnosistotreatmentintervalsaresignificantpredictorsofdiseaseprogressionandhospitalizationinhighriskpatientsarealworldanalysis AT imaizumikazuyoshi covid19symptomonsettodiagnosisanddiagnosistotreatmentintervalsaresignificantpredictorsofdiseaseprogressionandhospitalizationinhighriskpatientsarealworldanalysis AT itoyuji covid19symptomonsettodiagnosisanddiagnosistotreatmentintervalsaresignificantpredictorsofdiseaseprogressionandhospitalizationinhighriskpatientsarealworldanalysis AT okazawamitsushi covid19symptomonsettodiagnosisanddiagnosistotreatmentintervalsaresignificantpredictorsofdiseaseprogressionandhospitalizationinhighriskpatientsarealworldanalysis |